$51.55
4.619.82%
Last update: Nov 10, 7:20 AM
Scholar Rock Holding Corp
SRRKNASDAQ
Scholar Rock rose 75.5% from $29.37 to $51.55, ahead of the S&P 500's +10.5%. Its worst day was Oct 5 (−7.3%), and its low came Nov 10 at $29.37.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.90 missed the $-0.85 estimate on $0.00 revenue (est. $50,000.00).
+24.4%, the year's best day · S&P 500 0.0%
EPS of $-0.88 missed the $-0.87 estimate on $0.00 revenue (est. $2.3M).
Story events cover the past 12 months · Times ET
+1.9% · S&P 500 −0.9%
Scholar Rock shares rose 14.4%, while the S&P 500 fell 0.5%.
+14.4% · S&P 500 −0.5%
Apitegromab BLA resubmission includes Catalent Indiana LLC (part of Novo Nordisk) and second U.S.-based fill-finish facility, aligned with FDA guidance from March 3, 2026 Type C meetingFDA and Novo Nordisk Q1 2026
+14.1% · S&P 500 +2.9%
EPS of $-0.83 missed the $-0.79 estimate on $0.00 revenue (est. $4.0M).
−1.4% · S&P 500 −0.3%
EPS of $-0.84 beat the $-0.84 estimate on $0.00 revenue (est. $1.9M).
+10.0% · S&P 500 −0.2%
Scholar Rock closed at its highest level of the year, 104.4% above where the year started.
+3.1% · S&P 500 0.0%
Where it ended: a close of $51.55 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 10, 2026 (EPS est. $-0.85, revenue est. $278,936.00).
Nothing in the past 12 months.
All SRRK dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for SRRK and SPY from Benzinga historical bars. Not investment advice.
